Lv2
130 积分 2022-08-15 加入
Application of Neoadjuvant Docetaxel Plus Cisplatin in Early-Stage Triple-Negative Breast Cancer (HELEN-001): Results from a Phase II Trial
9小时前
已完结
Advances in HER2-Targeted Therapies: From monoclonal antibodies to dual inhibitors developments in cancer treatment
1个月前
已完结
Antibody-Drug Conjugates in Breast Cancer: The Road Towards Biologically-Informed Selection and Sequencing
2个月前
已完结
Efficacy of Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: A Comprehensive Systematic Review and Meta-analysis
2个月前
已完结
Sacituzumab Govitecan-hziy in Breast Cancer
2个月前
已完结
Sacituzumab govitecan for hormone receptor-positive HER2-negative advanced breast cancer
2个月前
已完结
Sacituzumab Govitecan: A Review in Unresectable or Metastatic HR+/HER2- Breast Cancer
2个月前
已完结
Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial
4个月前
已完结
Irinotecan and capecitabine combination chemotherapy in a patient with triple-negative breast cancer relapsed after adjuvant chemotherapy with anthracycline and taxane
5个月前
已完结
Review Article Third-line Treatment for Metastatic Triple-negative Breast Cancer A Systematic Review and Network Meta-analysis
5个月前
已完结
皖公网安备34019202002308
